Quantinuum IPO Planned by Honeywell

Honeywell said Jan. 14 that a confidential S-1 submission launches the Quantinuum IPO process, initiating SEC review and prompting investor reassessment.

January 14, 2026·2 min read
View all news articles
Flat vector of a quantum chip merging with a filing folder to symbolize the Quantinuum IPO confidential S-1 submission.

KEY TAKEAWAYS

  • Honeywell said it plans a confidential draft Form S-1 submission to the SEC for a Quantinuum IPO.
  • Number of shares and price range remain undetermined; offering depends on SEC review and market conditions.
  • Prior 2025 financing raised $600 million at a reported $10.0 billion valuation, framing market expectations.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Honeywell said in a press release on Jan. 14, 2026 ET that its majority-owned quantum computing unit Quantinuum plans to submit a confidential draft Form S‑1 registration statement to the U.S. Securities and Exchange Commission for a proposed IPO. The terms will be set after SEC review and depend on market conditions.

Confidential Form S‑1 Submission and Regulatory Notice

The company made the announcement under Rule 135 of the Securities Act of 1933, emphasizing that the statement does not constitute an offer to sell or solicit an offer to buy securities. Honeywell said it has not committed to completing any offering and that public details will be delayed as the SEC review proceeds.

The confidential filing initiates the SEC review process but leaves timing and pricing flexible. The number of shares and price range for the proposed offering have not been determined.

Quantinuum’s Funding, Scale, and IPO Context

Quantinuum was formed in 2021 by combining Honeywell Quantum Solutions and Cambridge Quantum. It operates as a full-stack quantum computing company, developing hardware, software, and cryptography. The business employs more than 630 people, including over 370 scientists and engineers, across the U.S., U.K., Germany, and Japan.

In 2025, Quantinuum raised $600 million from investors including a venture arm of Nvidia at a reported valuation of $10 billion. Sources close to the process have suggested an unverified potential valuation above $20 billion and a possible raise of about $1 billion. A separate report indicated a possible IPO window in late 2026 to 2027.

The confidential filing route allows Honeywell to maintain flexibility on timing and terms while beginning the SEC review. The prior funding and reported valuations provide a reference point for how the market might value the business ahead of a quantum computing IPO.

"Honeywell today announced that Quantinuum LLC, which is majority owned by Honeywell, plans to make a confidential submission of a draft registration statement on Form S‑1 to the U.S. Securities and Exchange Commission relating to the proposed initial public offering of Quantinuum's common stock," the company said in its press release.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Rolls-Royce Keeps FY2026 Guidance Despite Mideast Risk

Rolls-Royce Keeps FY2026 Guidance Despite Mideast Risk

Rolls-Royce FY2026 guidance held after an April 30 trading update; rising flying hours and divisional order strength underpinned profit and cash targets.

Microsoft Q3 2026 Earnings Show AI Cloud Momentum

Microsoft Q3 2026 Earnings Show AI Cloud Momentum

Microsoft Q3 2026 earnings show a $37.0 billion AI run rate and robust Azure demand, prompting traders to shift into AI infrastructure and cloud exposure.

Roblox Cuts Guidance Amid Safety Costs

Roblox Cuts Guidance Amid Safety Costs

Roblox cuts guidance as safety initiatives and a legal settlement curb near-term user growth; Q1 showed revenue and bookings gains but outlook was trimmed.

Amgen Q1 Results: Tavneos Update as Sales Rise

Amgen Q1 Results: Tavneos Update as Sales Rise

Amgen Q1 results showed stronger sales and an EPS beat that lifted FY2026 guidance and may shift positioning amid a Tavneos FDA withdrawal proposal.

Reddit Q1 Results Beat Estimates

Reddit Q1 Results Beat Estimates

Reddit Q1 results delivered a top-line beat led by surging ad revenue and stronger Q2 revenue guidance that should shape near-term trader positioning.

Rivian DOE Loan Amendment Boosts Georgia Plant Capacity

Rivian DOE Loan Amendment Boosts Georgia Plant Capacity

Rivian DOE loan amendment trims federal borrowing and expands Georgia capacity, prompting traders to watch the revised ramp, capex and midsize SUV timing